title: Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab.
abstract: Regarding the pathobiology of rheumatoid arthritis, oxidative stress induced by reactive oxygen species is an important mechanism that underlies destructive and proliferative synovitis. Abundant amounts of reactive oxygen species have been detected in the synovial fluid of inflamed rheumatoid joints. It is reported that drugs that block tumor necrosis factor-α reduce the oxidative stress marker levels in patients with rheumatoid arthritis. In this study, we measured reactive oxygen species using a free radical analytical system in patients with rheumatoid arthritis treated with disease-modifying antirheumatic drugs, tumor necrosis factor-α-blocking drugs (infliximab, etanercept), and an interleukin-6-blocking drug (tocilizumab). The serum level of oxidative stress was drastically low in patients with rheumatoid arthritis treated with tocilizumab, suggesting that interleukin-6 blocking therapy reduces not only joint damage, but also vascular degeneration in patients with rheumatoid arthritis. We believe that such a drastic effect would reduce the incidence of cardiovascular events and mortality in patients with rheumatoid arthritis.
authors: Department of Orthopaedics, Osaka University Graduate School of Medicine, Osaka, Japan.
authors: Makoto
authors: M
authors: Hirao
authors: Naomi
authors: N
authors: Yamasaki
authors: Hiroki
authors: H
authors: Oze
authors: Kosuke
authors: K
authors: Ebina
authors: Akihide
authors: A
authors: Nampei
authors: Yoshitaka
authors: Y
authors: Kawato
authors: Kenrin
authors: K
authors: Shi
authors: Hideki
authors: H
authors: Yoshikawa
authors: Norihiro
authors: N
authors: Nishimoto
authors: Jun
authors: J
authors: Hashimoto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D015850:Interleukin-6; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000097:blood; D018384:Oxidative Stress / Q000502:physiology*; D017382:Reactive Oxygen Species / Q000097:blood*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015415:Biomarkers; D015850:Interleukin-6; D017382:Reactive Oxygen Species; C502936:tocilizumab